How do I install the Endo Pa Mra Titrate Renin skill?

Run npx skillmds@latest add dromlakhani/endo-pa-mra-titrate-renin in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Pa Mra Titrate Renin safe to use?

SkillMD's automated safety review verdict for this skill is PASS. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Pa Mra Titrate Renin?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Pa Mra Titrate Renin free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Pa Mra Titrate Renin?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Pa Mra Titrate Renin by dromlakhani

Name: Endo Pa Mra Titrate Renin
Rating: 4.2 (5 reviews)
Author: dromlakhani

Endo Pa Mra Titrate Renin

In patients with primary aldosteronism receiving mineralocorticoid receptor antagonist therapy, the guideline recommends titrating the MRA dose upward to raise renin when blood pressure remains uncontrolled and renin is suppressed. Consider this step when hypertension is not at goal despite MRA therapy and plasma renin activity (or direct renin concentration) is low.

dromlakhani Updated Aug 19, 2026 10 repo stars

File contents

Titrate MRA dose to raise renin in PA patients with uncontrolled hypertension

STEP 1 — Gather Information

Confirm primary aldosteronism diagnosis, current MRA type and dose, seated morning blood pressure, plasma renin activity (PRA) or direct renin concentration (DRC), serum potassium, and estimated glomerular filtration rate (eGFR). Document these values to assess whether hypertension is uncontrolled and renin is suppressed.

STEP 2 — Rule In / Rule Out

If blood pressure is above target (e.g., ≥130/80 mmHg) AND renin is suppressed (PRA <0.5 ng/mL/h or DRC <4 mU/L), proceed to Step 3; otherwise, evaluate medication adherence, lifestyle factors, or consider adding other antihypertensive agents before increasing MRA dose.

STEP 3 — Classify or Stratify

Estimate the MRA dose increase based on current renin level: if renin is very low (PRA <0.2 ng/mL/h or DRC <2 mU/L), plan to increase spironolactone by 25–50 mg/day; if renin is low but detectable (PRA 0.2–0.5 ng/mL/h or DRC 2–4 mU/L), plan to increase by 25 mg/day; for eplerenone, use equivalent potency increments. Calculate the specific dose increment and prepare the new prescription.

STEP 4 — Decide

Increase the MRA dose as calculated, counsel the patient on adherence and dietary sodium restriction, and schedule reassessment of blood pressure and renin in 8–12 weeks.

Clinical Guardrails / Mimics / Pitfalls

Do not increase MRA if blood pressure is already at target; avoid doses that risk hyperkalemia (monitor K+ and creatinine); do not rely on renin rise alone if BP remains uncontrolled—add other agents; be cautious in CKD where renin response may be blunted.

Concrete Clinical Example

A 60-year-old woman with bilateral PA on spironolactone 50 mg daily presents with BP 148/92 mmHg, PRA 0.15 ng/mL/h, K+ 4.6 mmol/L, eGFR 68 mL/min/1.73m². Increase spironolactone to 75 mg daily and recheck BP and renin in 10 weeks.

Source: Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2025, DOI: 10.1210/clinem/dgaf284

TODO: consider adding scripts/calc.py for the endo-pa-mra-titrate-renin calculator

---name: endo-pa-mra-titrate-renindescription: In patients with primary aldosteronism receiving mineralocorticoid receptor antagonist therapy, the guideline recommends titrating the MRA dose upward to raise renin when blood pressure remains uncontrolled and renin is suppressed. Consider this step when hypertension is not at goal despite MRA therapy and plasma renin activity (or direct renin concentration) is low.---# Titrate MRA dose to raise renin in PA patients with uncontrolled hypertension## STEP 1 — Gather InformationConfirm primary aldosteronism diagnosis, current MRA type and dose, seated morning blood pressure, plasma renin activity (PRA) or direct renin concentration (DRC), serum potassium, and estimated glomerular filtration rate (eGFR). Document these values to assess whether hypertension is uncontrolled and renin is suppressed.## STEP 2 — Rule In / Rule OutIf blood pressure is above target (e.g., ≥130/80 mmHg) AND renin is suppressed (PRA <0.5 ng/mL/h or DRC <4 mU/L), proceed to Step 3; otherwise, evaluate medication adherence, lifestyle factors, or consider adding other antihypertensive agents before increasing MRA dose.## STEP 3 — Classify or StratifyEstimate the MRA dose increase based on current renin level: if renin is very low (PRA <0.2 ng/mL/h or DRC <2 mU/L), plan to increase spironolactone by 25–50 mg/day; if renin is low but detectable (PRA 0.2–0.5 ng/mL/h or DRC 2–4 mU/L), plan to increase by 25 mg/day; for eplerenone, use equivalent potency increments. Calculate the specific dose increment and prepare the new prescription.## STEP 4 — DecideIncrease the MRA dose as calculated, counsel the patient on adherence and dietary sodium restriction, and schedule reassessment of blood pressure and renin in 8–12 weeks.## Clinical Guardrails / Mimics / PitfallsDo not increase MRA if blood pressure is already at target; avoid doses that risk hyperkalemia (monitor K+ and creatinine); do not rely on renin rise alone if BP remains uncontrolled—add other agents; be cautious in CKD where renin response may be blunted.## Concrete Clinical ExampleA 60-year-old woman with bilateral PA on spironolactone 50 mg daily presents with BP 148/92 mmHg, PRA 0.15 ng/mL/h, K+ 4.6 mmol/L, eGFR 68 mL/min/1.73m². Increase spironolactone to 75 mg daily and recheck BP and renin in 10 weeks.**Source:** Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2025, DOI: 10.1210/clinem/dgaf284> **TODO:** consider adding scripts/calc.py for the endo-pa-mra-titrate-renin calculator

Frequently asked questions